This webinar will analyze two recent developments that could provide a boost to patent owners whose patents are threatened by AIA proceedings at the PTAB: the ongoing pilot program for motions to amend that was implemented in March 2019; and the USPTO’s clarification of how patent owners can use reissue and reexamination proceedings to amend patents during or even after an AIA review.
Panelists include a litigator who will share his first-hand experience of the new pilot, another experienced PTAB litigator, and an in-house lawyer at a pharma company that succeeded in amending claims after the October 2017 en banc Federal Circuit decision in Aqua Products Inc. The panel will discuss:
- the experience of parties in the first proceedings filed under the amendment pilot program. In early February, right before the webinar, the PTAB will hold the final oral hearing in Mylan v. Sanofi, the first filed under the new program.
- the USPTO guidance about reissue and re-exam, a reminder that the PTAB is not the only place to amend a patent. The time to completion for both traditional USPTO proceedings has shrunk because the case load of the Central Re-exam Unit has fallen with the growth of the PTAB’s.
Thursday, February 6, 2020
While we are pleased to have you contact us by telephone, surface mail, electronic mail, or by facsimile transmission, contacting Kilpatrick Townsend & Stockton LLP or any of its attorneys does not create an attorney-client relationship. The formation of an attorney-client relationship requires consideration of multiple factors, including possible conflicts of interest. An attorney-client relationship is formed only when both you and the Firm have agreed to proceed with a defined engagement.
DO NOT CONVEY TO US ANY INFORMATION YOU REGARD AS CONFIDENTIAL UNTIL A FORMAL CLIENT-ATTORNEY RELATIONSHIP HAS BEEN ESTABLISHED.
If you do convey information, you recognize that we may review and disclose the information, and you agree that even if you regard the information as highly confidential and even if it is transmitted in a good faith effort to retain us, such a review does not preclude us from representing another client directly adverse to you, even in a matter where that information could be used against you.